|
|
|
|
 |
|
Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah |
| Companies mentioned in this article: |
|
Biotech |
|
| 7/16/2008 @ 3:10 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Immunosyn Corporation (BULLETIN BOARD: IMYN) announced today that the distribution of SF-1019 in the State of Utah is anticipated to begin shortly through Renewed Hope Clinic in Beaver, Utah.
Immunosyn is negotiating an exclusive license agreement for the administration and distribution of SF-1019 in the State of Utah with Utah Biopharmaceutical Laboratories, LLC.
Immunosyn has been advised by Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic partner and its largest shareholder, that Argyll Biotech is negotiating a three-party agreement with its current domestic third party manufacturer and Utah Biopharmaceutical Laboratories for Utah Biopharmaceuticals Laboratories to be a third party manufacturer of SF-1019 in the State of Utah. Argyll Biotech has worked for several years on developing the manufacturing processes, protocols, safety procedures and guidelines for SF-1019. Immunosyn, together with Argyll Biotech and Utah Biopharmaceutical Laboratories, is working to finalize Distribution Management and Information Component Systems that will be implemented to define protocols to assure patient safety and regulatory compliance in Utah prior to treatment commencing.
The combination of the proposed license and manufacturing agreements will allow for SF-1019 to be administered in the State of Utah exclusively by Utah Biopharmaceutical Laboratories through Renewed Hope Clinic which is located in Beaver, Utah.
"I am excited to have the ability to treat patients with this therapeutic modality, which is not yet available elsewhere in the U.S. My review of the scientific background, preclinical testing, initial safety evaluations and studies performed under compassionate waivers, coupled with the therapeutic benefits I have witnessed, give me confidence in the benefit my patients will receive from SF-1019 treatment," said Mitchell J. Melling, MD, Manager of Utah Biopharmaceutical Laboratories, LLC.
Stephen D. Ferrone, President and CEO of Immunosyn, stated, "Utah Biopharmaceutical Laboratories sought the ability to distribute SF-1019 in the State of Utah as a result of the compelling desire of patients who are seeking this treatment after their having failed conventional, FDA approved therapy. This patient demand stemmed from the perceived benefit of treatment in patients who participated in early preclinical studies and who desire ongoing access to SF-1019 to alleviate their symptoms."
Ferrone added, "Argyll Biotech advises us that they plan to continue the process to obtain full regulatory approvals for the marketing of SF-1019 in both Europe and the U.S."
"This is an exciting early-stage development as this puts revenue producing capabilities within short-term range for the company," stated Douglas A. McClain, Jr., Chairman of the Board and CFO of Immunosyn.
About Utah Biopharmaceutical Laboratories, LLC
Utah Biopharmaceutical Laboratories was organized for the purpose of manufacturing SF-1019 for administering and distributing by United Biopharmaceutical Laboratories through the Renewed Hope Clinic under the direction of Mitchell J. Melling, MD in the State of Utah.
About Renewed Hope Clinic
Located in Beaver, Utah at 95 North 400 East, Renewed Hope Clinic is managed by Mitchell Melling, MD who is Board Certified in Family Practice in the State of Utah. Renewed Hope Clinic is a family practice center, emphasizing treatment of autoimmune and infectious diseases.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (BULLETIN BOARD: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the U.S. and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to www.immunosyn.com/). |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, September 5, 2008 |
 |
|
Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference Posted 3:28 PM PST
ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility Posted 3:18 PM PST
Digirad Corporation Developing New Cardiac Imaging System With Distortion Correction Posted 7:39 AM PST
|
| |
| Thursday, September 4, 2008 |
|
|
ZyGEM and Commonwealth Biotechnologies Announce Research Collaboration for DNA Extraction Products Posted 3:42 PM PST
Aethlon Medical Releases Shareholder Letter Posted 2:43 PM PST
Cypress Bioscience, Inc. to Participate in Citi's 3rd Annual Biotech Day Posted 7:59 AM PST
CliniComp Announces Agreement with Tenet Healthcare Corporation Posted 7:34 AM PST
Invitrogen Launches Patent Licensing Program for Enabling Amplification Technology Posted 7:29 AM PST
Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents Posted 7:02 AM PST
|
| |
| Wednesday, September 3, 2008 |
|
|
NuVasive to Present at Bank of America 38th Annual Investment Conference Posted 3:16 PM PST
Alacer Corp. Announces Emergen-C PINK College Tour to Build Breast Cancer Awareness Posted 3:08 PM PST
Nventa to Present at Upcoming Investor Conferences Posted 3:06 PM PST
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis Posted 3:04 PM PST
|
| |
| Tuesday, September 2, 2008 |
|
|
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis Posted 5:34 PM PST
Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies Posted 5:07 PM PST
NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference Posted 5:01 PM PST
Somaxon Presents Pharmacological Data on Doxepin at the 21st European College of Neuropsychopharmacology Congress Posted 4:18 PM PST
NuVasive to Present at Thomas Weisel Partners Healthcare Conference 2008 Posted 9:12 AM PST
Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib Posted 8:41 AM PST
Sequenom to Present at September Investment Conferences and to Hold Analyst and Investor Briefing Event Posted 8:12 AM PST
Aethlon Medical To Present at 2008 Southern California Investor Conference Southern California Investor Conference 2008 Posted 8:10 AM PST
Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial Posted 8:08 AM PST
Burnham Awarded $97.9 Million NIH Grant to Expand Small-Molecule Screening and Discovery Center Posted 7:47 AM PST
|
| |
| Thursday, August 28, 2008 |
|
|
Orexigen Therapeutics to Present at Upcoming Investor Conferences Posted 3:16 PM PST
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences Posted 3:15 PM PST
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference Posted 3:14 PM PST
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference Posted 3:13 PM PST
Volcano Presentation at Thomas Weisel Conference to Be Webcast Posted 3:12 PM PST
Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008 Posted 3:12 PM PST
Illumina to Present at Upcoming Investment Conferences in September Posted 7:43 AM PST
Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference Posted 7:42 AM PST
ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008 Posted 7:42 AM PST
|
| |
| Wednesday, August 27, 2008 |
|
|
Genoptix Announces Participation at the 2008 Southern California Investor Conference Posted 9:08 AM PST
|
| |
| Tuesday, August 26, 2008 |
|
|
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA Posted 3:42 PM PST
Cyntellect to Collaborate With the Burnham Institute for Medical Research; In situ live cell manipulation on LEAP to empower purification of stem cells and their differentiated progeny Posted 8:57 AM PST
TorreyPines Therapeutics Receives NASDAQ Deficiency Notice Posted 8:50 AM PST
JMAR Technologies Awarded Development Contract by the Johns Hopkins University Applied Physics Laboratory Posted 8:29 AM PST
Aperio Receives FDA Clearance for ER and PR Image Analysis Applications Posted 7:52 AM PST
|
| |
| Monday, August 25, 2008 |
|
|
Amylin and Lilly Set Date and Time for Conference Call; Companies Will Discuss Recent FDA Advisory Regarding BYETTA Posted 4:17 PM PST
Cripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer Posted 4:13 PM PST
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference Posted 4:12 PM PST
Invitrogen Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger with Applied Biosystems Posted 6:15 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
